You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):鴨坦布蘇病毒ELISA抗體檢測試劑盒取得獸藥產品批准文號
格隆匯 10-13 21:25

格隆匯10月13日丨瑞普生物(300119.SZ)公佈,公司全資子公司瑞普(保定)生物藥業有限公司近日獲得了由農業農村部核發的獸藥產品批准文號,具體如下:

鴨坦布蘇病毒病是由鴨坦布蘇病毒(DuckTambusuVirus,DTMUV)引起的以鴨採食量和產蛋量急劇下降、急性卵巢炎為臨牀特徵的一種新型急性傳染病,該病自2010年4月在我國福建、浙江等地發生以來,至今在我國主要養鴨地區以及越南、馬來西亞、泰國等多個國家廣泛流行,成為危害養鴨業的重要疫病之一。

鴨坦布蘇病毒ELISA抗體檢測試劑盒系採用具有中和鴨坦布蘇病毒活性、針對鴨坦布蘇病毒E蛋白的單克隆抗體建立的阻斷ELISA抗體檢測方法,具有很高的特異性、敏感性和重複性,可用於坦布蘇病毒抗體的快速定性和定量檢測,是坦布蘇病毒感染時大規模血清學流行病學調查和鴨坦布蘇病毒疫苗抗體檢測的首選工具之一。該試劑盒的成功研製和應用,填補了國際空白。

該新產品生產批文的獲得,結合公司前期研製的“鴨坦布蘇病毒病滅活疫苗(HB株)”(國家一類新獸藥)以及“鴨坦布蘇病毒血凝抑制試驗抗原、陽性血清與陰性血清”(國家一類新獸藥)系列產品,有助於進一步提高公司的核心競爭力及市場份額,為公司業績提供新的增長點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account